Cochrane · systematic review · CD001447
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, RG, Mitchell, JD, Moore, DH · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
NeuromuscularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 7 · 100%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: patients with ALS/MND
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality or tracheostomy at 12 months (pooled hazard ratio)(riluzole 100 mg) | HR 0.83 [0.7, 1] | 3 studies · 1282 participants | High |
Per cent mortality at 12 months (riluzole 100 mg) | RR 0.78 [0.65, 0.92] | 3 studies · 799 participants | High |
Rate of decline of Norris Scale ‐ Norris Limb (riluzole 100 mg) | no estimate extracted | 3 studies · 731 participants | High |
Rate of decline of Norris Scale ‐ Norris Bulbar (riluzole 100 mg) | no estimate extracted | 3 studies · 742 participants | High |
Adverse event: nausea | RR 1.55 [1.06, 2.28] | 3 studies · 801 participants | High |
Adverse event: asthenia | RR 1.5 [1.07, 2.12] | 3 studies · 801 participants | High |
Adverse event: 3‐fold increase in alanine transferase | RR 2.62 [1.59, 4.31] | 3 studies · 801 participants | High |